Literature DB >> 11712872

Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo.

T Bäcklund1, E Palojoki, T Grönholm, A Eriksson, O Vuolteenaho, M Laine, I Tikkanen.   

Abstract

The pharmacological profile of a vasopeptidase inhibitor is dependent on the ratio of neutral endopeptidase (NEP)vs angiotensin converting enzyme (ACE) inhibition of the particular drug. We used in vitro autoradiography to determine the local renal and cardiac NEP and ACE inhibition after oral treatment with the dual NEP/ACE inhibitor omapatrilat in rat. Maximal inhibition of both renal NEP and ACE was achieved at the omapatrilat dose of 40 mg kg(-1)day(-1). Effective local ACE inhibition was detected also in the myocardium. The haemodynamic effects were similar to captopril, but omapatrilat treatment produced more favorable effect on natriuretic peptide levels. In conclusion, good tissue penetration of omapatrilat and balanced NEP/ACE inhibition may prove to be useful in the treatment of hypertension and heart failure. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11712872     DOI: 10.1006/phrs.2001.0875

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  3 in total

1.  Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent.

Authors:  Stefan Schäfer; Hans-Ludwig Schmidts; Markus Bleich; Andreas E Busch; Wolfgang Linz
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

2.  Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema.

Authors:  R M Fryer; J Segreti; P N Banfor; D L Widomski; B J Backes; C W Lin; S J Ballaron; B F Cox; J M Trevillyan; G A Reinhart; T W von Geldern
Journal:  Br J Pharmacol       Date:  2007-12-17       Impact factor: 8.739

Review 3.  Exploring the Food and Drug Administration's review and approval of Entresto (sacubitril/valsartan).

Authors:  Ashley L Eadie; Keith R Brunt; Matthew Herder
Journal:  Pharmacol Res Perspect       Date:  2021-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.